ORIC Pharmaceuticals Analyst Ratings
ORIC Pharmaceuticals Analyst Ratings
ORIC Pharmaceuticals Analyst Ratings
Buy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical Pipeline
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
ORIC Pharmaceuticals Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Clinical Data and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
ORIC Pharmaceuticals Analyst Ratings
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
ORIC Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
ORIC Pharmaceuticals Analyst Ratings
ORIC Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating
ORIC Pharmaceuticals Analyst Ratings